Trifarotene, sold under the brand name Aklief, is a medication for the topical treatment of acne vulgaris.

[8][13][14] In December 2019, its labelling and package leaflet text received a decentralised approval for 16 European countries.

[7] In the United States, trifarotene is indicated for the topical treatment of acne vulgaris in people nine years of age and older.

[6] In both Canada and Australia, it is indicated for the topical treatment of acne vulgaris of the face and/or the trunk in people twelve years of age and older.

[1][2][3] Trifarotene was approved for medical use in the United States in October 2019,[14] in Canada in November 2019,[3] and in Australia in January 2021.